Qiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio

Reuters

2025/05/23

Qiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio

QIAGEN NV has announced a new partnership with ID Solutions, a French company specializing in digital PCR assays and molecular testing solutions for oncology. This collaboration aims to enhance QIAGEN's leadership in oncology-focused digital PCR assays by expanding the availability of these assays for non-clinical oncology research. The partnership will leverage QIAGEN's global reach and automation expertise alongside ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will produce dPCR assays for use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in various DNA samples. Initially launching in Europe, this partnership is set to broaden QIAGEN's portfolio and support the adoption of the QIAcuity dPCR platform in cancer research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522348645) on May 22, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537924087"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537924087\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537924087?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537924087","market":"us","top_or_hot":-1,"title":"Qiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN NV has announced a new partnership with ID Solutions, a French company specializing in digital PCR assays and molecular testing solutions for oncology. This collaboration aims to enhance QIAGEN's leadership in oncology-focused digital PCR assays by expanding the availability of these assays for non-clinical oncology research. The partnership will leverage QIAGEN's global reach and automation expertise alongside ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will produce dPCR assays for use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in various DNA samples. Initially launching in Europe, this partnership is set to broaden QIAGEN's portfolio and support the adoption of the QIAcuity dPCR platform in cancer research.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522348645) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-23 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN NV has announced a new partnership with ID Solutions, a French company specializing in digital PCR assays and molecular testing solutions for oncology. This collaboration aims to enhance QIAGEN's leadership in oncology-focused digital PCR assays by expanding the availability of these assays for non-clinical oncology research. The partnership will leverage QIAGEN's global reach and automation expertise alongside ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will produce dPCR assays for use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in various DNA samples. Initially launching in Europe, this partnership is set to broaden QIAGEN's portfolio and support the adoption of the QIAcuity dPCR platform in cancer research.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522348645) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909247.SGD","symbol_name":"Natixis Thematics Meta H-R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL4ctppM:1","article_id":"2537924087","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537924087","pubTimestamp":1747944353,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"QIAGEN NV has announced a new partnership with ID Solutions, a French company specializing in digital PCR assays and molecular testing solutions for oncology. This collaboration aims to enhance QIAGEN's leadership in oncology-focused digital PCR assays by expanding the availability of these assays for non-clinical oncology research. The partnership will leverage QIAGEN's global reach and automation expertise alongside ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will produce dPCR assays for use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in various DNA samples. Initially launching in Europe, this partnership is set to broaden QIAGEN's portfolio and support the adoption of the QIAcuity dPCR platform in cancer research.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","BK4121":"生命科学工具和服务","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","QGEN":"快而精医药","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC"},"translate_title":"Qiagen NV与ID Solutions合作增强数字PCR肿瘤研究产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"Qiagen NV Partners with ID Solutions to Enhance Digital PCR Oncology Research Portfolio\n    \n\n        QIAGEN NV has announced a new partnership with ID Solutions, a French company specializing in digital PCR assays and molecular testing solutions for oncology. This collaboration aims to enhance QIAGEN's leadership in oncology-focused digital PCR assays by expanding the availability of these assays for non-clinical oncology research. The partnership will leverage QIAGEN's global reach and automation expertise alongside ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will produce dPCR assays for use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in various DNA samples. Initially launching in Europe, this partnership is set to broaden QIAGEN's portfolio and support the adoption of the QIAcuity dPCR platform in cancer research.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522348645) on May 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}